I know someone mentioned to stop coming up with ideas to
I know someone mentioned to stop coming up with ideas to solve the PPS issue because we don’t have all the information...that person is totally right that we don’t have all the information and like I said before, I think joe is a genius, I am sure he will come up with something if he has not already. For someone who brought up a company from ashes in less than 3 years and the PPS went up 2000% under his reign, I am sure he will figure out a way to get gnbt uplisted soon!
But a thought just popped into my head...just for fun I thought I’d share it and see if it makes any remote sense to people who are interested in participating in this brain storming fun session and please ignore me if you are not interested in participating...
This is the thought...not sure how well it would work and whether it is possible legally...but here it is...gnbt is planning on doing rights offering of ngio shares...would it be possible to tie the numbers of ngio shares a Gnbt shareholder can buy at dirt cheap price to the number of gnbt shares the person owns. For example, for each 1000 gnbt shares you own, you can buy 200 shares of ngio share at a penny. And if the person who owns 1000 gnbt shares wants to buy more than 200 ngio shares, any ngio shares over 200 would cost $1 each let’s say (still at a discount but not even close to the penny deal)..that should cause people to want to buy more gnbt shares.
So, let’s say I have 1200 gnbt shares, I would probably buy at least 800 more gnbt shares, so I can buy 400 ngio shares at a penny...Gnbt shareholders rounding up their share counts to the nearest thousand may help drive up the PPS. Also there may be people who may want to buy gnbt shares in one thousand increments so they can take advantage of the penny deal.
Gnbt will probably have around 70 million outstanding gnbt shares after the 1:1 dividend, so the most number of ngio shares that will be sold at a penny would be 14 million (not everyone will take advantage since there are lots of dormant investors) , which is less than the 15 million shares that was given out because of the 1:4 dividend.
Also noticing all the current gnbt shareholders of the ngio penny opportunity may wake up some dormant gnbt shareholders and they may decide to do some research and figure out that joe is doing a phenomenal job and see the incredible upside potential and start buying gnbt shares and take advantage of ngio shares penny deal.
And to avoid people selling gnbt shares right after getting the penny deal..maybe add some kind of condition...e.g. the number of gnbt shares used to take advantage of the penny deal become restricted...can’t sell those until 30 days after gnbt is uplisted...haha...
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Unpacking the MediaLight Launch Kicking off September, XKL is tossing its hat in the ring with the MediaLight Xponder and Muxponder systems. These aren't just any run-of-the-mill gizmos—nope, they're touted as top-of-the-line optical transport solutions. The talk of the town is their ability to dish out high-density 100G and 400G transport, and for geeks in the trade,...
Continue Reading
Out in Texas, folks facing iron deficiency have a new game-changer coming their way. Drip Gym, the same outfit making waves out in Queens and Long Island, is taking their mobile iron IV therapy clinic straight to Texan doorsteps. No more trotting off to a clinic for iron infusions with this crew rolling into Houston, Dallas, Austin, and San Antonio. What's the Big Deal?...
Continue Reading
Pressure Builds for EquipmentShare Investors If you've thrown some cash into EquipmentShare.com Inc. (NASDAQ: EQPT), it's time to sit up and pay attention. There's smoke on the horizon, and Faruqi & Faruqi, LLP is waving the flag. They've got a securities class action spinning fast, and if you've suffered any losses, September 21, 2026, is a date you don't want to forget....
Continue Reading
AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...
Continue Reading
A Strategic Move Across the Pacific Well, folks, in an era where the seas aren't just blue but powered by tech-backed autonomy, here's a new chapter—the kind that doesn't just hint at innovation, it screams it. Havoc, that crafty leader in all things autonomous, inked a game-changing deal with Taiwan's shipbuilding behemoth, CSBC Corporation. They're not just building...
Continue Reading
What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...
Continue Reading
Breaking Ground in Tech Deployment The march toward commercializing new tech can be a nightmare. Ask any innovator trying to leap from lab genius to market ready, and they'll tell you the pathway is paved with hurdles—especially in the rough-and-tumble world of energy and industrial tech. RTI International's latest $14 million move? That's a massive step in leveling the...
Continue Reading
Mining's Often Overlooked Obstacle: Land Access In the world of mining, the shallow thrills of striking gold are often overshadowed by the frustrating slog of securing land access. You can have your permits lined up, your finances sorted, and drills humming along, but if you haven’t sweet-talked the folks farming above your visible vein of riches, you could be staring...
Continue Reading
Industry Gears Up for Financial Action Clearly, cannabis businesses are shouting louder than a vendor at a ballgame, demanding more than just the basic chips-and-soda banking service. They’re on the hunt for serious credit facilities, payments, and the traditional financial tools that most sectors take for granted. I mean, check this out: Shield Compliance just dropped...
Continue Reading
Understanding What Constitutes Bad Faith Insurance What does it really mean when an insurer acts in "bad faith"? Well, the legal standard doesn't leave much wiggle room in California. These aren't just bad outcomes; we're talking about conduct that defies what's reasonable under state law. Demián I. Oksenendler, a seasoned bad faith attorney, shed some light on this in a...
Continue Reading
Top 5 Most Recently Viewed Articles
Intel Sees Unprecedented Stock Surge Intel Corp. (NASDAQ: INTC) is experiencing remarkable growth in its stock performance, achieving its most impressive week in over two decades. The driving force behind this impressive surge stems from strong political backing, particularly from the former President. This support has energized market enthusiasm as investors speculate on...
Continue Reading
Understanding the Class Action Lawsuit for Transocean Ltd. Investors Transocean Ltd. is currently facing a class action lawsuit that has garnered significant attention among its investors. This situation arises as the company strives to manage its asset portfolio and navigate the complexities of its business model. What Led to the Class Action Filing? The Law Offices of...
Continue Reading
Overview of Biohaven Ltd.'s Recent Developments Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company, has made remarkable strides in its drug development and therapeutic pipeline. Recently, the company announced significant updates on its product advancements, particularly focusing on its innovation in therapeutic platforms. Biohaven's recent developments highlight...
Continue Reading
Innovative Treatment for Skin Toxicities in Cancer Patients Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on creating innovative solutions for unmet medical needs, has reached an important milestone with its new therapy, HT-001. This innovative treatment specifically targets skin toxicities associated with epidermal growth factor receptor...
Continue Reading
AMG Sees Significant Growth in First Quarter Results AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) has announced impressive financial results for the first quarter of 2025, marking a substantial growth compared to the previous year. With a revenue of $388 million, this reflects an 8% increase from $358 million in the same period last year....
Continue Reading